Clinical Trials Browser

Phase 1/2 × mirvetuximab soravtansine × 1 year × Clear all

NCT06390995 2025-06-15

A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors

Phase 1/2 Active not recruiting

Ovarian Neoplasms